Markets:

Overview

News

Currencies

International

Treasuries

Gilead Sciences (NQ:GILD)

151.40 +0.28 (+0.19%)

Streaming Delayed Price Updated: 4:00 PM EST, Feb 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

51 52 Next >

Goldman Sachs Thinks Mid-Cap Biotech MoonLake Could Soar Over 80%: Is Retail Watching Closely? ↗

January 17, 2025

Oppenheimer has included MoonLake among its top biotech picks for 2025, alongside Capricor, Gilead, Kymera, Praxis, and Prothena.

Via Stocktwits

This McDonald's Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday ↗

January 10, 2025

Via Benzinga

Obesity Treatments, M&A Activity To Take Center Stage During Upcoming JPM Healthcare Conference ↗

January 09, 2025

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.

Via Benzinga

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus ↗

January 08, 2025

Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.

Via Benzinga

Looking Into Gilead Sciences's Recent Short Interest ↗

January 07, 2025

Via Benzinga

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today ↗

January 06, 2025

Via Benzinga

(GILD) - Analyzing Gilead Sciences's Short Interest ↗

December 19, 2024

Via Benzinga

Is GILEAD SCIENCES INC Ready to Break Out of Its Range? ↗

December 19, 2024

In-Depth Technical Analysis of GILEAD SCIENCES INC.

Via Chartmill

Marjorie Taylor Greene Went Christmas Shopping For Stocks, Here's What She Bought Before Holiday ↗

December 31, 2024

Marjorie Taylor Greene spent part of Christmas Eve buying stocks according to recent disclosures. Here's what she bought.

Via Benzinga

Healthcare And Biotech Stocks Continue Their Slide ↗

December 30, 2024

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

Via Talk Markets

Topics ETFs Stocks / Equities

Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout. ↗

December 25, 2024

GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know.

Via Chartmill

Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More ↗

December 22, 2024

JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.

Via Benzinga

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today ↗

December 16, 2024

Via Benzinga

What Analysts Are Saying About Gilead Sciences Stock ↗

December 10, 2024

Via Benzinga

Looking At Gilead Sciences's Recent Unusual Options Activity ↗

December 03, 2024

Via Benzinga

Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study? ↗

December 20, 2024

The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future.

Via Investor's Business Daily

COVID-19 is Not the Same Disease for Everyone

December 20, 2024

(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated...

Via Brandpoint

Topics Death

Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report ↗

December 13, 2024

ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends.

Via Benzinga

Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing ↗

December 12, 2024

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

Via Benzinga

Price Over Earnings Overview: Gilead Sciences ↗

November 25, 2024

Via Benzinga

26 Analysts Assess Gilead Sciences: What You Need To Know ↗

November 18, 2024

Via Benzinga

Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead. ↗

December 09, 2024

The companies held competing events on Sunday to discuss their multiple myeloma treatments.

Via Investor's Business Daily

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients ↗

December 09, 2024

Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes.

Via Benzinga

Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease ↗

November 15, 2024

Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety.

Via Benzinga

Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low ↗

November 15, 2024

The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows.

Via Benzinga

Topics Government

3 Spectacular High-Yield Dividend Stocks to Buy in November ↗

November 10, 2024

High yields aren't a warning indicator with these three stocks.

Via The Motley Fool

Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks ↗

November 08, 2024

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and...

Via Benzinga

Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review ↗

November 08, 2024

A Fed rate cut and a slew of big earnings reports filled out a busy week.

Via Investor's Business Daily

Topics Economy Government

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook ↗

November 07, 2024

Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence.

Via Benzinga

Topics Earnings

< Previous 1 2

...

12 13 14 15 16 17 18 19 20

...

51 52 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Gilead Sciences (NQ:GILD)

Headline News about Gilead Sciences

Starting at $3.75/week.

Subscribe Today